利妥昔单抗在初治与难治性炎性肌病中的疗效比较:来自三级医疗中心的经验
该研究基于前瞻性维护数据库,纳入60例特发性炎性肌病患者(33例初治、27例难治),比较利妥昔单抗的疗效。随访6个月时,初治组31/31(100%)有治疗反应,难治组17/24(70%)有治疗反应,P=0.006;初治组MMT8评分平均改善13.41(s.d. 7.31),难治组改善8.33(s.d. 7.92),P=0.017。作者结论认为利妥昔单抗在整个特发性炎性肌病谱系中有效且安全,早期使用与更好结局相关。
要点
- 随访6个月时初治组31/31(100%)有治疗反应,难治组17/24(70%)有治疗反应,P=0.006。
- 初治组MMT8评分平均改善13.41(s.d. 7.31),难治组改善8.33(s.d. 7.92),P=0.017。
- 中位随访24个月(四分位距36)内未报告重大不良事件。
核心结论
- 利妥昔单抗在整个特发性炎性肌病谱系中有效且安全,疾病早期使用与更好结局相关。
研究设计与样本
- 数据来自前瞻性维护的数据库,纳入接受利妥昔单抗治疗的特发性炎性肌病患者。
- 共纳入60例特发性炎性肌病患者(包括18例抗信号识别颗粒肌病),其中33例为初治接受利妥昔单抗,其余27例因难治性肌病开始利妥昔单抗。
- 初治组平均年龄39岁(s.d. 12.58),难治组平均年龄43岁(s.d. 12.12)。
- 在基线、3个月和6个月间隔及后续随访时收集患者资料,治疗反应根据MMT8评分、患者整体和医生整体对皮肤及关节症状改善的评价以及6个月时的肺量计检查,分为改善、恶化或稳定。
主要发现
- 随访6个月时,48/55(87%)患者显示治疗反应,其中初治组31/31(100%)有治疗反应,难治组17/24(70%)有治疗反应,P=0.006。
- 难治组中7例(29%)疾病稳定。
- 初治组MMT8评分平均变化为13.41(s.d. 7.31),难治组为8.33(s.d. 7.92),初治组改善显著更多(P=0.017)。
- 大多数患者能够在6个月前将剂量减至<5 mg/天。
- 中位随访24个月(四分位距36)内未报告重大不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine whether rituximab (RTX) is effective in 'treatment-naïve' idiopathic inflammatory myopathies (IIM), and whether there could be differential treatment responses between 'treatment-naïve' and treatment 'refractory' IIM. METHODS: Data were obtained from a prospectively maintained database comprising patients with IIM treated with RTX. Patient details were obtained at baseline, 3- and 6-months intervals, and at subsequent follow-up visits. Treatment response was categorized as improved, worsening or stable based on Manual Muscle Testing 8 (MMT8) scores, patient global and physician global improvement for skin and joint symptoms improvement, and spirometry at 6 months. The time to clinical improvement and remission were noted and survival analysis curves were constructed. RESULTS: Sixty patients with IIM (including 18 with anti-signal recognition particle myopathy) were included, of whom 33 who received RTX were treatment naïve. The remaining 27 were started on RTX for refractory myopathy. The mean age was 39 years (s.d. 12.58) in the 'treatment-naïve' group and 43 years (s.d. 12.12) in the 'refractory' group. At 6 months of follow-up, 48/55 (87%) patients showed response, 31/31 (100%) in 'treatment-naïve' and 17/24 (70%) in 'refractory' cases, P = 0.006*. In the refractory group, seven (29%) had stable disease. The mean changes in MMT8 were significantly more in the 'treatment-naïve' group [13.41 (s.d. 7.31)] compared with 'refractory' IIM [8.33 (s.d. 7.92)] (P = 0.017*). The majority of patients were able to reduce the dose to <5 mg/day before 6 months. No major adverse events were reported over the median follow-up of 24 (interquartile range 36) months. CONCLUSIONS: RTX is effective and safe across the spectrum of IIM. Early use in disease is associated with better outcomes.
引用
- Manwatkar A, Naresh K, Mathew J, et al. Comparison of rituximab efficacy in treatment-naïve and refractory inflammatory myopathies: experiences from a tertiary care centre. Rheumatology (Oxford). 2025. PMID: 38814804. doi:10.1093/rheumatology/keae307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。